Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs.

X-linked myotubular myopathy (XLMTM) results from MTM1 gene mutations and myotubularin deficiency. Most XLMTM patients develop severe muscle weakness leading to respiratory failure and death, typically within 2 years of age. Our objective was to evaluate the efficacy and safety of systemic gene therapy in the p.N155K canine model of XLMTM by performing a dose escalation study. A recombinant adeno-associated virus serotype 8 (rAAV8) vector expressing canine myotubularin (cMTM1) under the muscle-specific desmin promoter (rAAV8-cMTM1) was administered by simple peripheral venous infusion in XLMTM dogs at 10 weeks of age, when signs of the disease are already present. A comprehensive analysis of survival, limb strength, gait, respiratory function, neurological assessment, histology, vector biodistribution, transgene expression, and immune response was performed over a 9-month study period. Results indicate that systemic gene therapy was well tolerated, prolonged lifespan, and corrected the skeletal musculature throughout the body in a dose-dependent manner, defining an efficacious dose in this large-animal model of the disease. These results support the development of gene therapy clinical trials for XLMTM.

• Publication year

  2017

• Venue

  Molecular Therapy

• Publication date

  2017-04-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ymthe.2017.02.004PMID 28237839PMCID PMC5383631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Common Data Elements for Muscle Biopsy Reporting.

  2016cited by this paper
• Gene therapy in monogenic congenital myopathies.

  2016cited by this paper
• Novel findings associated with MTM1 suggest a higher number of female symptomatic carriers

  2016cited by this paper
• Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons

  2016cited by this paper
• Muscle pathology, limb strength, walking gait, respiratory function and neurological impairment establish disease progression in the p.N155K canine model of X-linked myotubular myopathy.

  2015influential reference
• Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

  2015cited by this paper
• Validity of a Neurological Scoring System for Canine X-Linked Myotubular Myopathy

  2015cited by this paper
• Determination of Anti-Adeno-Associated Virus Vector Neutralizing Antibody Titer with an In Vitro Reporter System

  2015cited by this paper
• Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus.

  2015cited by this paper
• Gait characteristics in a canine model of X-linked myotubular myopathy.

  2014influential reference
• Tissue Triage and Freezing for Models of Skeletal Muscle Disease

  2014cited by this paper
• Differential muscle hypertrophy is associated with satellite cell numbers and Akt pathway activation following activin type IIB receptor inhibition in Mtm1 p.R69C mice.

  2014cited by this paper
• Our Journey to Successful Gene Therapy for Hemophilia B

  2014cited by this paper
• Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.

  2014cited by this paper
• Gene Therapy Prolongs Survival and Restores Function in Murine and Canine Models of Myotubular Myopathy

  2014influential reference
• Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy.

  2013influential reference
• Automated fiber-type-specific cross-sectional area assessment and myonuclei counting in skeletal muscle.

  2013cited by this paper
• Engraftment of a Galactose Receptor Footprint onto Adeno-associated Viral Capsids Improves Transduction Efficiency*

  2013cited by this paper
• Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors

  2012cited by this paper
• Muscle function in A canine model of X‐linked myotubular myopathy

  2012cited by this paper
• Establishing clinical end points of respiratory function in large animals for clinical translation.

  2012influential reference
• Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates.

  2011cited by this paper
• Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

  2011cited by this paper
• D³ Data-Driven Documents

  2011cited by this paper
• A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8.

  2011cited by this paper
• Systemic administration of AAV8-α-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression.

  2011cited by this paper
• Muscle‐directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors

  2011cited by this paper
• In vivo canine muscle function assay.

  2011cited by this paper
• Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle

  2010cited by this paper
• Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

  2010cited by this paper
• MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers

  2010cited by this paper
• Centronuclear myopathies: a widening concept.

  2010cited by this paper
• Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy.

  2010cited by this paper
• AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis

  2008cited by this paper
• Centronuclear (myotubular) myopathy

  2008cited by this paper
• Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.

  2007cited by this paper
• Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.

  2006cited by this paper
• Medical complications in long-term survivors with X-linked myotubular myopathy.

  1999cited by this paper
• Contraction force generated by tarsal joint flexion and extension in dogs with golden retriever muscular dystrophy.

  1999cited by this paper
• Characterization of the myotubularin dual specificity phosphatase gene family from yeast to human.

  1998cited by this paper
• Color Use Guidelines for Mapping and Visualization

  1994cited by this paper
• Changes in linear dimensions of the heart, relative to body weight, as measured by M-mode echocardiography in growing dogs.

  1991cited by this paper
• Centronuclear ("myotubular") myopathy.

  1969cited by this paper

• AAV8 gene therapy and dietary insults together precipitate cholestatic liver disease in a mouse model of X-linked myotubular myopathy.

  2026cites this paper
• Engineered muscle tissues with enhanced maturation enable the identification of clinically relevant rAAV capsids

  2026cites this paper
• A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease

  2025cites this paper
• microRNA-133a as an indicator of disease progression and treatment response in X-linked myotubular myopathy

  2025cites this paper
• X-linked myotubular myopathy: an untreated treatable disease

  2025cites this paper
• Myosin inhibition partially rescues the myofiber proteome in X-linked myotubular myopathy

  2025cites this paper
• CRISPR/Cas13-mediated Dynamin 2 reduction therapy in a canine model of DNM2-related centronuclear myopathy

  2025cites this paper
• Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy.

  2025cites this paper
• Integrative Approaches to Myopathies and Muscular Dystrophies: Molecular Mechanisms, Diagnostics, and Future Therapies

  2025cites this paper
• Expanding the Potential of Gene Therapy for Duchenne Muscular Dystrophy.

  2025cites this paper
• Current Clinical Applications of AAV-mediated Gene Therapy.

  2025cites this paper
• Have a Little Heart (or Not): Highly Minimized Skeletal Muscle Regulatory Cassettes with Low or No Activity in the Heart

  2024cites this paper
• An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species

  2024cites this paper
• Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?

  2024cites this paper
• Potential compensatory mechanisms preserving cardiac function in myotubular myopathy

  2024cites this paper
• A healthcare claims analysis to identify and characterize patients with suspected X-Linked Myotubular Myopathy (XLMTM) in the Brazilian Healthcare System

  2024cites this paper
• 261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands.

  2023cites this paper
• High-throughput transcriptome analyses from ASPIRO, a phase 1/2/3 study of gene replacement therapy for X-linked myotubular myopathy.

  2023cites this paper
• Preclinical Development and Characterization of Novel Adeno-Associated Viral Vectors for the Treatment of Lipoprotein Lipase Deficiency

  2023cites this paper
• The Ice Age - A Review on Formulation of Adeno-Associated Virus Therapeutics.

  2023cites this paper
• Real-world analysis of healthcare resource utilization by patients with X-linked myotubular myopathy (XLMTM) in the United States

  2023cites this paper
• Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice

  2023cites this paper
• X-linked myotubular myopathy: a clinical report and a review of the mild phenotype

  2023cites this paper
• Current Strategies of Muscular Dystrophy Therapeutics: An Overview.

  2023cites this paper
• ADENO-ASSOCIATED VIRUSES IN GENE THERAPY FOR SPINAL MUSCULAR ATROPHIES: TREND OR TRIUMPH?

  2023cites this paper
• Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trial

  2023cites this paper
• Congenital myopathies.

  2023cites this paper
• Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial.

  2023cites this paper
• Neuromuscular disease: Gene transfer for children: What we know now

  2022cites this paper
• Gene therapy in neuromuscular disorders

  2022cites this paper
• Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders

  2022cites this paper
• Serotype-Speci�c Transduction of Canine Joint Tissue Explants and Cultured Monolayers by Self-Complementary Adeno-Associated Viral Vectors

  2022cites this paper
• Serotype-specific transduction of canine joint tissue explants and cultured monolayers by self-complementary adeno-associated viral vectors

  2022cites this paper
• INCEPTUS Natural History, Run-in Study for Gene Replacement Clinical Trial in X-Linked Myotubular Myopathy

  2022cites this paper
• X‐linked myotubular myopathy associated with an MTM1 variant in a Maine coon cat

  2022cites this paper
• Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species.

  2021cites this paper
• X-linked myotubular myopathy.

  2021cites this paper
• Intrathymic AAV gene transfer rapidly restores thymic function and long-term persistence of gene-corrected T cells

  2021cites this paper
• Gene Therapy for Duchenne Muscular Dystrophy

  2021cites this paper
• Hepatobiliary disease in XLMTM: a common comorbidity with potential impact on treatment strategies

  2021cites this paper
• Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies

  2021cites this paper
• Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog

  2021cites this paper
• Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies

  2021cites this paper
• Respiratory care in myotubular myopathy

  2021cites this paper
• Voluntary wheel running complements microdystrophin gene therapy to improve muscle function in mdx mice

  2021cites this paper
• Expression Cassette Design and Regulation of Transgene Expression

  2021cites this paper
• Genetic diseases in the omics era.

  2021cites this paper
• Muscular dystrophy-dystroglycanopathy in a family of Labrador retrievers with a LARGE1 mutation.

  2021cites this paper
• Cellular, Tissue, and Gene Therapies Advisory Committee September 2-3, 2021 Meeting Briefing Document- FDA

  2021cites this paper
• Common Pathogenic Mechanisms in Centronuclear and Myotubular Myopathies and Latest Treatment Advances

  2021cites this paper
• Current Clinical Applications of In Vivo Gene Therapy with AAVs

  2020cites this paper
• Intrathymic AAV gene transfer rapidly restores thymic function and long-term persistence of gene-corrected T cells.

  2020cites this paper
• AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer

  2020cites this paper
• Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans

  2020cites this paper
• Deriving Immune Modulating Drugs from Viruses—A New Class of Biologics

  2020cites this paper
• Targeted Treatments for Inherited Neuromuscular Diseases of Childhood

  2020cites this paper
• Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy

  2020cites this paper
• Broader Implications of Progressive Liver Dysfunction and Lethal Sepsis in Two Boys following Systemic High-Dose AAV

  2020cites this paper
• rAAV-related therapy fully rescues myonuclear and myofilament function in X-linked myotubular myopathy

  2020cites this paper
• In Situ Detection of Adeno-associated Viral Vector Genomes with SABER-FISH

  2020cites this paper
• Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back

  2020cites this paper
• Progress and challenges of gene therapy for Pompe disease.

  2019cites this paper
• Gene transfer to skeletal muscle using hydrodynamic limb vein injection: current applications, hurdles and possible optimizations

  2019cites this paper
• AAV-Mediated Gene Transfer Restores a Normal Muscle Transcriptome in a Canine Model of X-Linked Myotubular Myopathy.

  2019influential citation
• Pathological Issues in Dystrophinopathy in the Age of Genetic Therapies.

  2019cites this paper
• X-linked myotubular myopathy

  2019cites this paper
• Gene Therapy for X-Linked Myotubular Myopathy

  2019cites this paper
• Histological and Biochemical Evaluation of Muscle Gene Therapy

  2019cites this paper
• Neuromuscular Diseases of the Newborn.

  2019cites this paper
• Gene Therapy for Pompe Disease: The Time is now

  2019cites this paper
• Systemic AAV8-mediated delivery of a functional copy of muscle glycogen phosphorylase (Pygm) ameliorates disease in a murine model of McArdle disease.

  2019cites this paper
• X‐linked myotubular myopathy and pulmonary blebs: Not just a muscle disorder

  2019cites this paper
• Mortality and respiratory support in X-linked myotubular myopathy: a RECENSUS retrospective analysis

  2019cites this paper
• The Dog Model in the Spotlight: Legacy of a Trustful Cooperation

  2019influential citation
• TNNT1 nemaline myopathy: natural history and therapeutic frontier

  2018cites this paper
• Centronuclear myopathy: advances in genetic understanding and potential for future treatments

  2018cites this paper
• Gene therapy strategies for X-linked myotubular myopathy

  2018influential citation
• Recent advances in understanding congenital myopathies

  2018cites this paper
• AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice

  2018cites this paper
• Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy

  2018cites this paper
• Dose-Dependent Effects of FKRP Gene-Replacement Therapy on Functional Rescue and Longevity in Dystrophic Mice

  2018cites this paper
• Centronuclear myopathies under attack: A plethora of therapeutic targets

  2018cites this paper
• Molecular Therapies for Muscular Dystrophies

  2018cites this paper
• Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients

  2018cites this paper
• Myotonia congenita in a Labrador Retriever with truncated CLCN1.

  2018cites this paper
• The progress of AAV-mediated gene therapy in neuromuscular disorders

  2018cites this paper
• Intravenous Administration of a MTMR2-Encoding AAV Vector Ameliorates the Phenotype of Myotubular Myopathy in Mice

  2018cites this paper
• The genetics of congenital myopathies.

  2018cites this paper
• Gene therapy approach on Charcot-Marie-Tooth type 1A rats

  2018cites this paper
• AAV-mediated gene transfer restores a normal muscle transcriptome in a canine model of X-linked myotubular myopathy

  2018cites this paper
• Frontiers in Muscle Diseases: The X-ray Microtomography Support to Latest Researches

  2018cites this paper
• Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase

  2017cites this paper
• Modélisation et analyses physiopathologiques de la Sclérose Latérale Amyotrophique liée à l'ubiquiline 2 à l'aide de vecteurs AAV10

  2017cites this paper
• A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model.

  2017cites this paper
• Systemic AAV Gene Therapy Close to Clinical Trials for Several Neuromuscular Diseases.

  2017cites this paper
• Long‐term effects of systemic gene therapy On gait in a canine model of myotubular myopathy

  2017cites this paper
• Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.

  2017cites this paper
• Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape.

  2017cites this paper
• Linker proteins restore basement membrane and correct LAMA2-related muscular dystrophy in mice

  2017cites this paper
• Long‐term effects of systemic gene therapy in a canine model of myotubular myopathy

  2017influential citation